US Broker Ratings

Galapagos NV (GLPG) Stock Analysis: Navigating a -22% Downside with Biotechnology Prospects

Galapagos NV (NASDAQ: GLPG) is a notable player in the biotechnology sector, focusing on pioneering treatments in oncology and immunology. Despite a challenging financial landscape, Galapagos’ strategic collaborations and innovative..

Biohaven Ltd. (BHVN) Stock Analysis: A Biotech Powerhouse with a Stunning 192.80% Potential Upside

Biohaven Ltd. (NASDAQ: BHVN) is making waves in the biotechnology sector with a significant potential upside of 192.80%, making it an intriguing option for investors seeking opportunities in the healthcare..

Disc Medicine, Inc. (IRON) Stock Analysis: Unleashing a 69% Growth Potential in the Biotech Sector

For investors with an eye for potential and innovation in the healthcare sector, Disc Medicine, Inc. (NASDAQ: IRON) presents a captivating opportunity. This clinical-stage biopharmaceutical company, headquartered in Watertown, Massachusetts,..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Exploring a 17% Potential Upside with Strong Buy Ratings

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is capturing the attention of investors in the biotechnology sector, particularly due to its promising pipeline and a significant analyst-backed potential upside of 17.39%. With..

Bausch Health Companies Inc. (BHC) Stock Analysis: Navigating Potential Upside Amidst Healthcare Dynamics

Bausch Health Companies Inc. (NYSE: BHC) stands as an intriguing player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. With a diverse portfolio encompassing gastroenterology,..

Alvotech (ALVO) Investor Outlook: Exploring a Potential 94% Upside with Biosimilar Innovations

Alvotech (NASDAQ: ALVO), a pioneering company in the healthcare sector, is gaining attention in the drug manufacturing industry, particularly in the realm of specialty and generic biosimilars. Based in Luxembourg,..

Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring a 112% Upside Potential in the Biotech Sector

Denali Therapeutics Inc. (NASDAQ: DNLI) stands at the forefront of innovation in the biotechnology industry, focusing on therapeutics for neurodegenerative and lysosomal storage diseases. With a market capitalization of $2.17..

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: A 27% Potential Upside Beckons Investors

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a pioneer in the biotechnology sector, stands out with a compelling growth narrative driven by its innovative focus on cellular metabolism treatments. With a market..

Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring a 223% Potential Upside in Biotech Innovation

Janux Therapeutics, Inc. (NASDAQ: JANX) has emerged as a compelling player in the biotech sector, capturing investor attention with a remarkable potential upside of 223%. As a clinical-stage biopharmaceutical company,..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: A Glimpse into Its 21.62% Potential Upside

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a leading player in the healthcare sector under the Medical Instruments & Supplies industry, is presenting a potential investment opportunity that might capture the attention..

National HealthCare Corporation (NHC) Stock Analysis: A Stable Dividend Play with Robust Revenue Growth

National HealthCare Corporation (NYSE: NHC) stands as a notable player in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $1.67 billion, the company..

LivaNova PLC (LIVN) Stock Analysis: Healthcare Innovator’s 21% Upside Potential Captures Investor Attention

LivaNova PLC (NASDAQ: LIVN), a prominent player in the healthcare sector, has become a focal point for investors seeking opportunities in medical technology. The company, headquartered in London, operates in..

Liquidia Corporation (LQDA) Stock Analysis: A Biotech Growth Story with 32% Potential Upside

Liquidia Corporation (NASDAQ: LQDA) is capturing investor attention with its significant 32.28% potential upside, as suggested by analyst ratings. As a key player in the biotechnology sector, the company is..

Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Analysis: 37.9% Potential Upside Drives Strong Investor Interest

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) is capturing investor attention with a compelling growth narrative and a substantial 37.9% potential upside based on analyst ratings. Specializing in developing therapies for unmet..

BGM Group Ltd. (BGM) Stock Analysis: Navigating Challenges in the Healthcare Sector

BGM Group Ltd. (BGM), entrenched in the specialized niche of Drug Manufacturers – Specialty & Generic within the healthcare sector, is a company that has captured attention for its unique..

Twist Bioscience Corporation (TWST) Stock Analysis: A Healthcare Innovator with 42.76% Potential Upside

Twist Bioscience Corporation (NASDAQ: TWST) stands out in the healthcare sector, particularly within diagnostics and research. With its innovative approach to synthetic DNA-based products, the company offers a unique value..

Vericel Corporation (VCEL) Stock Analysis: Exploring a 48% Upside Potential with Strong Buy Ratings

Vericel Corporation (NASDAQ: VCEL), a prominent player in the biotechnology sector, has captured the attention of investors with its innovative approach to cellular therapies and specialty biologic products. Based in..

Guardian Pharmacy Services, Inc (GRDN) Stock Analysis: Exploring a Potential 10% Upside in the Healthcare Sector

Guardian Pharmacy Services, Inc. (NASDAQ: GRDN) emerges as a compelling opportunity for investors seeking exposure in the healthcare sector, particularly in the niche of pharmacy services for long-term care facilities..

Zai Lab Limited (ZLAB)

⚠️ No article content returned.

..

Perrigo Company plc (PRGO) Stock Analysis: Navigating a 48.72% Potential Upside with Robust Dividends

Perrigo Company plc (NYSE: PRGO), a staple in the healthcare sector, is making waves in the investor community with a noteworthy 48.72% potential upside, according to analyst ratings. As a..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds